Windtree Therapeutics (WINT) said Wednesday it has tapped New Growth Advisors as its strategic adviser to lead a potential transaction process for its cardiovascular portfolio.
New Growth Advisors will help manage the current inbound interest and run an expanded out-licensing process for the portfolio, Windtree said.
The company said it's looking to secure potentially non-dilutive financing through a partnership for istaroxime and the oral SERCA2a activators for all global territories excluding Greater China.
In Greater China, Windtree has a licensing deal for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals for which it could receive as much as $138 million in potential milestones and low-double-digit royalties.
Windtree said Lee's expects to launch phase 3 in acute heart failure in its licensed territory in H1 2025.
Windtree shares were down 13.5% in recent trading.
Price: 0.47, Change: -0.07, Percent Change: -13.52
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。